Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tociluzumab for Cytokine Release Syndrome With SARS-CoV-2
NCT04361552Phase 3Withdrawn
- Sponsor
- Emory University
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in cytokine release syndrome (CRS), Coronavirus Disease 2019 (COVID-19), sponsored by Emory University. Planned start Apr 2020; status: withdrawn.
02
Drugs
tocilizumab
03
Conditions
cytokine release syndrome (CRS)Coronavirus Disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04361552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361552.